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Rare adverse effects in a patient treated with atypical antipsychotics
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Case Report
Second generation or atypical antipsychotics are well
established as an effective treatment for schizophrenia.
They are also safe alternatives to classical antipsychotics in
respect of adverse effects like hyperprolactinemia, extrapy-
ramidal side effects (EPS), and akathisia. However in
some cases, side effects considered not to differ signifi-
cantly from placebo might occur, complicated treatment
decision. We report the case of a patient who presented
hyperprolactinemia and amenorrhea after olanzapine
administration, extrapyramidal side effects with ziprasi-
done treatment, and, finally, akathisia after aripiprazole
administration.
G. is a 30 year-old woman with psychotic disorder NOS
who was admitted in our department and treated with
olanzapine (initiated at 20 mg/day and decreased at 15
mg/day afterwards). After one month, hyperprolactine-
mia and amenorrhea were observed. A decrease of the
dose to 10 mg/day led to a relapse of psychotic sympoms,
resulting to the patient's rehospitalization. Olanzapine
was replaced with ziprasidone 120 mg/day, and shortly
afterwards, prolactin levels and the menstrual cycle
returned to normal. However, she gradually developed
severe EPS, which did not improve much with a decrease
in daily dosage (100 mg/day), nor after the addition of
biperidin. Despite sufficient improvement of her psycho-
pathology, a change of antipsychotic regime was decided,
as five weeks after initiation of ziprasidone, the severe EPS
remained. Aripiprazole was selected to replace ziprasi-
done, and after a two-week cross-tapering the patient
received aripiprazole 30 mg/day. A significant
improvemet of the EPS was noticed, but severe akathisia
emerged. This side effect continued even after 6 weeks of
treatment and despite the addition of lorazepam to her
regime. Consequently, aripiprazole dosing was decreased
to 20 mg/day resulting in amelioration of akathisia, while
the patient remained clinically stable.
Second generation antipsychotics are an effective and safe
treatment option patients with schizophrenia and other
psychotic disorders. Their main contribution in psychop-
harmacology is their reduced potential for side effects that
classical antipsychotics commonly produce due to their
long association time with D2 receptors and/or the
absence of 5HT2A antagonism. However rare, the possi-
bility remains that atypical antipsychotics might induce
side effects like hyperprolactinemia, EPS and akathisia, in
patients presenting an intrinsic vulnerability for unknown
reasons.
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